Analyst Price Target is $2.50
▲ +2,786.84% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for RVL Pharmaceuticals in the last 3 months. The average price target is $2.50, with a high forecast of $3.00 and a low forecast of $2.00. The average price target represents a 2,786.84% upside from the last price of $0.09.
Current Consensus is
The current consensus among 3 investment analysts is to moderate buy stock in RVL Pharmaceuticals. This Moderate Buy consensus rating has held steady for over two years.
RVL Pharmaceuticals plc, a specialty pharmaceutical company, focuses on the development and commercialization of pharmaceutical products that target markets with underserved patient populations in the ocular and medical aesthetics therapeutic areas in the United States, Argentina, and Hungary. It is commercializing Upneeq (RVL-1201), an oxymetazoline hydrochloride ophthalmic solution, for the treatment of acquired blepharoptosis, or low-lying eyelid in adults. The company was formerly known as Osmotica Pharmaceuticals plc and changed its name to RVL Pharmaceuticals plc in January 2022. RVL Pharmaceuticals plc is headquartered in Bridgewater, New Jersey.